EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer

  • End date
    Jan 1, 2027
  • participants needed
  • sponsor
    University of Virginia
Updated on 26 January 2021
antiandrogen therapy
androgen suppression
external beam radiation therapy
digital rectal exam
digital rectal examination


This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, and overall survival for patients receiving this treatment.

Condition Malignant neoplasm of prostate, Prostate Cancer, Prostate Cancer, Early, Recurrent, Prostatic disorder, Prostate Disorders, Prostate Disorders, Prostate Cancer, Early, Recurrent, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Adenocarcinoma of Prostate, Prostate Cancer, prostate carcinoma, prostate cancers
Treatment Androgen Deprivation Therapy, External beam radiation, HDR Brachytherapy
Clinical Study IdentifierNCT04465500
SponsorUniversity of Virginia
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male, aged 18 or above
Histologic proven diagnosis of cancer of the prostate within one year of registration
Unfavorable-intermediate risk, high risk, or very high-risk prostate cancer as determined by the NCCN Guidelines Version 4.2019
History and physical exam completed up to 6 months before registration
PSA value < 50 ng/mL prior to androgen deprivation therapy and up to 6 months before registration
ECOG performance status 0 or 1
Pelvic MRI obtained up to 6 months before registration

Exclusion Criteria

Evidence of bone metastases
Diagnosis of a prior invasive malignancy (except for non-melanoma skin cancer), unless the participant has been disease-free for at least 3 years
Patient has had previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Patient has had previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Patient has had prior radiotherapy, including brachytherapy, to the region of this study cancer that would result in overlap of radiation therapy fields
Patient has had previous or concurrent cytotoxic chemotherapy for prostate cancer (prior chemotherapy for different cancer is allowed)
Patient has MRI incompatible metallic implant(s) that cannot be removed
The patient has severe or active co-morbidities as defined by the following
Unstable angina and/or congestive heart failure requiring hospitalization within 6 months (180 days) of registration
Transmural myocardial infarction within 6 months (180 days) of registration
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
Hepatic insufficiency resulting in clinical jaundice and/or coagulation effects or severe liver dysfunction
Acquired immune deficiency syndrome (AIDS) based upon current CDC definition. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be slightly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note